Trial · NCT04531137
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change of body weight | Baseline (after signing the consent) week-0, week-4, week-8, and week-12 (endline) | to investigate the change of body weight before, during and after intervention. Using Seca® type 876 is calibrated scale to the nearest 0.1 kilogram. The lower body weight indicates better outcome |
| Primary | Change of body fat mass | Baseline (after signing the consent) week-0 and week-12 (endline) | to investigate the change of body fat mass before and after intervention. Using Dual-energy X-ray absorptiometry (DXA GE Lunar® Prodigy 64179). The lower body fat mass indicates better outcome |
| Primary | Change of body fat mass | Baseline (after signing the consent) week-0, week-4, week-8, and week-12 (endline) | to investigate the change of body fat mass before, during, and after intervention. Using Bod Pod (Cosmed®). The lower body fat mass indicates better outcome |
| Secondary | Change of Waist hip ratio | Baseline (after signing the consent) week-0, week-4, week-8, and week-12 (endline) | to investigate the change of waist hip ratio before, during, and after intervention. Waist hip ratio is obtained by dividing the waist circumference and hip circumference. Tape measurement (Seca® type 201) is calibrated scale to nearest 0.1 centimeter. The lower body fat mass indicates better outcome |
| Secondary | Change of Low Density Lipoprotein (LDL) | Baseline (after signing the consent) week-0 and week-12 (endline) | to investigate the change of low density lipoprotein (LDL) in miligram per deciliter before and after intervention. The lower change of LDL indicates the better outcome. Enzymatic method |
| Secondary | Change of High Density Lipoprotein (HDL) | Baseline (after signing the consent) week-0 and week-12 (endline) | to investigate the change of high density lipoprotein (HDL) in miligram per deciliter before and after intervention. The higher change of HDL indicates the better outcome. Enzymatic method |
| Secondary | Change of Total of Cholesterol | Baseline (after signing the consent) week-0 and week-12 (endline) | to investigate the change of total of cholesterol in miligram per deciliter before and after intervention. The lower change of total of cholesterol indicates the better outcome. Enzymatic method |
| Secondary | Change of Triglyceride | Baseline (after signing the consent) week-0 and week-12 (endline) | to investigate the change of triglyceride in miligram per deciliter before and after intervention. The lower change of triglyceride indicates the better outcome. Enzymatic method |
| Secondary | Dietary intake (semi quantitative food frequency questionnaire) | Baseline (after signing the consent) week-0, week-8 and week-12 (endline) | to investigate the dietary intake before, during, and after intervention using semi quantitative food frequency questionnaire. The higher number of dietary intake indicates the better outcome |
| Secondary | Dietary intake (24-hours recall) | Baseline (after signing the consent) week-0, week-8 and week-12 (endline) | to investigate the dietary intake before, during, and after intervention using 24-hours recall. The higher dietary intake indicates the better outcome |
| Secondary | Change of knowledge | Baseline (after signing the consent) week-0 and week-12 (endline) | to investigate the score of knowledge before and after the intervention. Using validated questionnaire of knowledge. Minimum score is 0 and maximum score is 100.The higher score of knowledge after intervention indicates the better outcome. |
| Secondary | Change of attitude | Baseline (after signing the consent) week-0 and week-12 (endline) | to investigate the score of attitude before and after the intervention. Using validated questionnaire of attitude. Minimum score is 0, maximum score is 100. The higher score of attitude after intervention indicates the better outcome. |
| Secondary | Physical activity level | Baseline (after signing the consent) week-0, week-4, week-8, and week-12 (endline) | to investigate the physical activity level before, during and after intervention. Using International Physical Activity Questionnaire. The category of physical activity level are low (\<600 metabolic equivalents), moderate (\>=600 - 3000 metabolic equivalents) and high (\>=3000 metabolic equivalents). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04531137/registered